Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Deuterium-depleted water (DDW)** is water with a reduced deuterium (²H) concentration, typically below 150 ppm compared to ~150 ppm in natural water, produced as a byproduct of heavy water isolation. It exhibits altered physical properties like lower density, viscosity, and surface tension due to deuterium's influence on water cluster formation and stronger O-D bonds.[2][6] Preclinical studies suggest DDW inhibits cancer cell proliferation (e.g., colorectal cancer via oxidative stress modulation), enhances insulin sensitivity and GLUT4 translocation in diabetes models, and extends survival in cancer patients retrospectively; mechanisms may involve metabolic disruption in deuterium-sensitive processes like mitochondrial function and cell division, though clinical evidence remains limited.[1][3][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deuterium-depleted water.